UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported): June 10, 2011
Integra LifeSciences Holdings Corporation
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-26244
|
|
510317849 |
|
|
|
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.) |
|
|
|
311 Enterprise Drive, Plainsboro,
New Jersey
|
|
08536 |
|
|
|
(Address of principal executive
offices)
|
|
(Zip Code) |
Registrants telephone number, including area code: 609-275-0500
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
|
|
|
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Private Offering
In
a press release issued on June 10, 2011, Integra LifeSciences Holdings Corporation (the
Company) announced the pricing of its offering of $200 million aggregate principal amount of
senior convertible notes due 2016 (the notes) in a private placement, subject to market
conditions and other factors. The Company has granted the initial purchasers of the notes options
to purchase up to an additional $30 million aggregate principal amount of the notes within 30 days
of the initial issuance of the notes solely to cover over-allotments.
In accordance with Rule 135c(d) under the Securities Act, a copy of the press release is
attached hereto as Exhibit 99.1.
|
|
|
Item 9.01 |
|
Financial Statement and Exhibits. |
|
|
|
|
|
|
99.1 |
|
|
Press
Release of Integra LifeSciences Holdings Corporation, dated June 10, 2011. |